The FDA's Peptide Vote: What Actually Happened in July 2026
An FDA advisory panel narrowly voted to allow six of seven peptides (including BPC-157) to be compounded, directly against the advice of the FDA's own scientific staff, who cited insufficient safety and efficacy evidence for all seven.
Sustainable Performance
This is a regulatory development rather than a research study, but it belongs here because it directly shapes what happens to popular wellness peptides. In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides, including BPC-157, KPV, TB-500, MOTS-c, epitalon and semax, for possible addition to the list of substances compounding pharmacies may legally prepare. In its briefing documents, the FDA's own scientific staff recommended against adding any of the seven, citing a lack of evidence on safety and effectiveness. The 14-member panel disagreed on most counts: several votes were narrow, and six of the seven peptides received majority support, with only emideltide rejected. It is worth being precise about what this does and does not mean: an advisory committee recommendation is not FDA approval, does not make these peptides legal to compound today, and formal rulemaking, which can take well over a year, is still required. The tension between staff caution and panel enthusiasm is itself the story.
Master Midlife Transformation
Return to your Calm Power
